Investor Presentation Full Year 2017

Investor Presentation Full year 2017 Slide 65 VictozaⓇ maintains a 14% value market share in the GLP-1, SGLT-2 and DPP-IV segment Segment value Share of segment value growth Segment value market shares DKK billion 250 100% 12% 12% 200 80% CAGR¹ value: 26.1% 150 60% 100 40% VictozaⓇ Other GLP-1 SGLT-2 DPP-IV 100% 80% 60% 40% VictozaⓇ: 14% 50 20% 20% 0% 0% Nov 2012 1 CAGR for 5-year period Note: Segment only includes DPP-IV, GLP-1 & SGLT-2. Other oral anti-diabetic agents and insulin excluded Source: IQVIA (formerly IMS) MAT Nov, 2017 value figures Nov 2017 2015 vs 2016 2016 vs Nov 2017 2012 Nov 2017 changing diabetes® novo nordisk

View entire presentation